Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Long-Term Investments (2021 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Long-Term Investments for 5 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 81.04% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, down 81.04% year-over-year, with the annual reading at $4.3 million for FY2025, 81.04% down from the prior year.
  • Long-Term Investments hit $4.3 million in Q4 2025 for Bolt Biotherapeutics, down from $6.9 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $85.3 million in Q4 2021 to a low of $4.3 million in Q4 2025.
  • Historically, Long-Term Investments has averaged $34.8 million across 5 years, with a median of $28.5 million in 2023.
  • Biggest five-year swings in Long-Term Investments: skyrocketed 49.89% in 2022 and later tumbled 81.04% in 2025.
  • Year by year, Long-Term Investments stood at $85.3 million in 2021, then plummeted by 71.95% to $23.9 million in 2022, then increased by 10.32% to $26.4 million in 2023, then fell by 13.38% to $22.9 million in 2024, then plummeted by 81.04% to $4.3 million in 2025.
  • Business Quant data shows Long-Term Investments for BOLT at $4.3 million in Q4 2025, $6.9 million in Q3 2025, and $13.7 million in Q2 2025.